List of Excipients in Branded Drug FENTANYL CITRATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Pharmaceuticals USA Inc	FENTANYL CITRATE	fentanyl citrate	0093-7865	ANHYDROUS CITRIC ACID
Teva Pharmaceuticals USA Inc	FENTANYL CITRATE	fentanyl citrate	0093-7865	DEXTRATES
Teva Pharmaceuticals USA Inc	FENTANYL CITRATE	fentanyl citrate	0093-7865	MAGNESIUM STEARATE
Teva Pharmaceuticals USA Inc	FENTANYL CITRATE	fentanyl citrate	0093-7865	MODIFIED CORN STARCH

Generic Drugs Containing FENTANYL CITRATE

Company	Ingredient	NDC	Excipient
SpecGx LLC	fentanyl citrate	0406-9202	ALCOHOL
SpecGx LLC	fentanyl citrate	0406-9202	AMMONIA
SpecGx LLC	fentanyl citrate	0406-9202	CITRIC ACID MONOHYDRATE
SpecGx LLC	fentanyl citrate	0406-9202	DEXTRATES

What are the Most Frequently-Used Excipients in FENTANYL CITRATE?

# Of NDCs	Excipient
1	ALCOHOL
1	AMMONIA
1	CITRIC ACID MONOHYDRATE
1	DEXTRATES

Excipient Strategy and Commercial Opportunities for Fentanyl Citrate

Last updated: February 27, 2026

Fentanyl citrate is a potent synthetic opioid primarily used for pain management, anesthesia, and postoperative analgesia. Its formulation impacts efficacy, stability, bioavailability, and abuse deterrence, which in turn influence commercial viability.

What is the Role of Excipients in Fentanyl Citrate Formulations?

Excipients are inactive ingredients that support drug stability, delivery, and manufacturability. For fentanyl citrate, excipients influence:

• Solubility and stability: Required to maintain fentanyl’s chemical integrity.
• Absorption: Excipients can modify pharmacokinetics to optimize onset and duration.
• Patient safety: Choice of excipients affects allergenicity and tolerability.
• Abuse deterrence: Special excipients can hinder tampering.

Common Excipients in Fentanyl Citrate Products

Solubilizing Agents

• Ethanol: Enhances solubility in injectable forms.
• Propylene glycol: Used in transdermal patches to facilitate drug release.

Buffering Agents

• Citric acid or sodium citrate: Maintain pH stability in solutions.

Preservatives

• Benzoates: Prevent microbial growth in multi-use solutions, though rarely in patches.

Matrix-Forming Polymers

• Polyethylene glycol (PEG): Used in transdermal systems for controlled release.
• Povidone (PVP): Stabilizes formulations and improves solubility.

Deterrent Excipient Strategies

• Incorporation of antagonists (e.g., naloxone) in abuse-deterrent formulations.
• Use of excipients that increase formulation viscosity to prevent crushing.

Formulation Types and Excipient Strategies

Injectable Solutions

• Require high purity of solvents like ethanol and stabilizers such as sodium citrate.
• Emphasize sterilization-compatible excipients.

Transdermal Patches

• Utilize adhesives (e.g., acrylic polymers), matrix-forming polymers (PEG), and penetration enhancers.
• Designed for controlled, sustained drug release and abuse deterrence.

Sublingual and Buccal Films

• Use film-forming polymers (hydroxypropyl methylcellulose) with plasticizers (glycerol).

Oral and Nasal Forms

• Excipient approaches focus on solubilizers and viscosity agents for rapid absorption.

Commercial Opportunities Linked to Excipient Strategy

Abuse-Deterrent Formulations (ADF)

• Marketed products include excipients that prevent tampering.
• Increased demand due to opioid misuse concerns.

Extended-Release Systems

• Use of matrix-forming polymers extends release, reducing abuse potential.
• Growing market segment aligned with regulatory shifts.

Cost Optimization

• Selecting cost-effective excipients that meet regulatory demands enables margin improvements.
• Use of excipients with streamlined supply chains reduces manufacturing costs.

Regulatory and Patent Challenges

• Novel excipient combinations can be patented, creating barriers to generic entry.
• Complexity of excipient platforms can delay approval but protect market share.

Future R&D Directions

• Excipient innovation to enable multi-modal delivery (e.g., combined systemic and local effects).
• Development of excipients that improve taste masking and patient acceptability.

Regulatory Landscape Impacting Excipient Choices

• US FDA requires excipients in controlled-release formulations to be Generally Recognized As Safe (GRAS).
• European Medicines Agency(s) monitor excipient safety and compatibility.
• Novel excipients demand extensive safety and stability testing.

Market Size and Growth Projections

Segment	Market Value (USD billion, 2022)	CAGR (2023-2028)
Transdermal fentanyl sales	4.2	5.2%
Abuse-deterrent formulations	1.5	6.5%
Extended-release formulations	2.8	4.8%

Increased adoption of abuse-deterrent and sustained-release products drives revenue growth, with excipient innovation as a core differentiator.

Key Takeaways

• Excipients in fentanyl citrate formulations are critical for stability, delivery, patient safety, and abuse deterrence.
• Opportunities exist in developing abuse-resistant formulations using specialized excipients.
• Cost-effective excipient choices and patent protection influence competitive positioning.
• Regulatory compliance influences excipient selection and formulation complexity.
• Market expansion is driven by demand for advanced delivery systems with improved safety profiles.

FAQs

1. What are the primary challenges in excipient selection for fentanyl citrate?

Ensuring excipient compatibility, safety, stability, and regulatory approval while achieving desired pharmacokinetic profiles.

2. How do excipients contribute to abuse-deterrent formulations?

They can increase the physical or chemical resistance to tampering or incorporate antagonists that prevent misuse.

3. What are emerging trends in excipient innovations for fentanyl products?

Use of biodegradable polymers, tamper-resistant matrices, and novel penetration enhancers.

4. What regulatory considerations impact excipient choices?

Excipients must meet safety standards (e.g., GRAS in the US), and novel excipients require comprehensive testing and approval.

5. How does excipient strategy influence market competitiveness?

Formulations with advanced excipients can command premium prices, secure patent protection, and meet regulatory and safety standards.

---

References

[1] U.S. Food and Drug Administration. (2021). Guidance for Industry: Abuse-Deterrent Opioids—Evaluation and Labeling.
[2] European Medicines Agency. (2022). Reflection Paper on the Use of Excipients in Modified Release Oral Products.
[3] Grand View Research. (2023). Opioid Market Analysis and Forecast.
[4] Smith, J. A., & Lee, K. H. (2022). Advances in Abuse-Deterrent Formulation Technologies. Journal of Pharmaceutics, 15(3), 120-135.